drugset
drugset / Trial / NCT07059650

DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)

NCT07059650 ↗

Phase 1/2 Recruiting 150 enrolled Dizal Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This study will treat patients with diffuse large B-cell lymphoma (DLBCL). It will assess the anti-tumor efficacy and safety of DZD8586 combination therapy by using objective response rate and the incidence and severity of adverse events. It will also measure the levels of DZD8586 in the body when combined with immunochemotherapy regimens.

Timeline

Start
2025-08-19
Primary completion
2030-10
Completion
2030-10

Drugs

EvaluationDrugModalityDoseRoute
Subject DZD8586 Unknown 50 mg Oral
Subject DZD8586 Unknown 75 mg Oral
Background Bendamustine Small molecule 90 mg/m2 Intravenous
Background Cyclophosphamide Other / unclassified 750 mg/m2 Intravenous
Background Doxorubicin Other / unclassified 50 mg/m2 Intravenous
Background Gemcitabine Small molecule 1000 mg/m2 Intravenous
Background Oxaliplatin Small molecule 100 mg/m2 Intravenous
Background Prednisone Other / unclassified 100 mg Oral
Background Rituximab Monoclonal antibody 375 mg/m2 Intravenous
Background Vincristine Small molecule 1.4 mg/m2 Intravenous

Indications

diffuse large B-cell lymphoma